Registration is open for 2027!
Launched in 2013, CEoT has established itself as AST's focused, high-impact winter meeting. Now in its 15th year, CEoT continues to bring together clinical and translational experts from the fields of chronic disease, end-stage organ disease, and solid organ transplantation.
For the first time in program history, CEoT 2027 moves to a single-track general session format built around seven cutting-edge sessions rather than organ-specific breakouts. This shift reflects where the science is heading. Advances in machine perfusion, medical AI, regenerative medicine, and xenotransplantation are not organ-specific. They are reshaping care across kidney, liver, heart, lung, and pancreas transplantation at the same time, and clinicians need a shared forum to evaluate them together instead of in separate silos.
The program is designed to deepen understanding of these advances, confront the ethical and practical questions they raise, and give attendees a working sense of which innovations are close to clinical reality and which still need years of development. Sessions move from gene editing and organ bioprinting, to foundation model AI in transplant care, to Treg-based tolerance therapies, regenerative organ and islet engineering, molecular diagnostics for graft health, and the current state of xenotransplantation. An AST Board Emerging Topic session and a Future of Transplantation Think Tank round out the meeting, giving attendees room to weigh in on where the field goes next.
As indicated by the name, CEoT emphasizes the dissemination of cutting-edge ideas that advance healthcare delivery and expand novel patient-centered initiatives, giving the field a place to translate emerging science into practical, clinical impact.
Conference Learning Objectives
Following this activity, attendees should be able to:
1. Evaluate emerging technologies, including machine perfusion, gene editing, organ bioprinting, and regenerative and xenotransplantation approaches, for their current and near-term role in solid organ transplantation.
2. Describe how artificial intelligence and novel diagnostic tools are being applied to clinical decision-making and graft health monitoring in transplantation.
3. Identify ethical, regulatory, and patient-centered considerations that must be addressed as these innovations move toward clinical adoption.
Advertisements
